Pasithea Therapeutics Stock Price, News & Analysis
Company Description
Pasithea Therapeutics (NASDAQ: ktta) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $17.8M, ranking #6,185 among all listed U.S. companies by market cap.
ktta stock has declined 35.3% over the past year. Shares last traded at $0.7699.
On a trailing twelve-month basis, Pasithea Therapeutics reported net income of -$20.4M and diluted earnings per share of $-2.91.
This page provides a comprehensive overview of ktta stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Pasithea Therapeutics (ktta) stock last traded at $0.7699. Over the past 12 months, the stock has lost 35.3%. At a market capitalization of $17.8M, ktta is classified as a micro-cap stock with approximately 24.9M shares outstanding.
Latest News
Pasithea Therapeutics has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial, offering. View all ktta news →
SEC Filings
Pasithea Therapeutics has filed 5 recent SEC filings, including 2 Form SCHEDULE 13G/A, 1 Form 10-K, 1 Form SCHEDULE 13G, 1 Form 8-K. The most recent filing was submitted on March 30, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ktta SEC filings →
Financial Highlights
operating income reached -$20.9M, and net income was -$20.4M. Diluted earnings per share stood at $-2.91. The company generated -$15.2M in operating cash flow. With a current ratio of 11.35, the balance sheet reflects a strong liquidity position.
Upcoming Events
PAS-004 data presentation
Pasithea Therapeutics has 1 upcoming scheduled event. The next event, "PAS-004 data presentation", is scheduled for July 1, 2026 (in 86 days). Investors can track these dates to stay informed about potential catalysts that may affect the ktta stock price.
Short Interest History
Short interest in Pasithea Therapeutics (ktta) currently stands at 194.4 thousand shares, up 12.0% from the previous reporting period, representing 0.9% of the float. Over the past 12 months, short interest has decreased by 53.4%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Pasithea Therapeutics (ktta) currently stands at 2.9 days, up 145.3% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 187% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.9 days.
ktta Company Profile & Sector Positioning
Pasithea Therapeutics (ktta) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing ktta often look at related companies in the same sector, including 60 degrees pharmaceuticals, Inc. (SXTP), Titan Pharmaceut (TTNP), Palisade Bio Inc (PALI), Aditxt Inc (ADTX), and TNF Pharmaceuticals (TNFA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ktta's relative position within its industry.